The study protocol is organized in two phases: the short-term follow-up and the long-term follow-up.~PD patients in need of IPG replacement will be screened for enrollment eligibility.~For the short-term follow-up, randomized patients will undergo 2 days of experimental sessions (i.e. one per each type of stimulation mode, cDBS and aDBS), in a well-controlled environment (i.e. during hospitalization). This part of the study will collect information on safety and potential efficacy endpoints as assessed by experienced neurologists. The short term follow-up phase will be considered complete when the endpoint assessment has been performed for all patients.~Patients, who will not experience severe side effects and who will be deemed suitable by the neurologist, will be eligible to continue in the long-term follow-up phase (i.e. 1 month) in their home environment. The AlphaDBS System will deliver the stimulation in aDBS or cDBS mode, for two weeks in each mode.
The aim of this study is to assess the safety and the potential efficacy of personalized Local Field Potential (LFP)-based adaptive Deep Brain Stimulation (aDBS), using the implantable pulse generator (IPG) of the AlphaDBS System, in Parkinson's Disease patients, chronically implanted in subthalamic nucleus (STN) for DBS, at the time of IPG replacement.